AnaptysBio’s Immuno-Oncology Collaboration Profiled in Nature Biopharma...
September 1st, 2014 ANAPTYSBIO’S IMMUNO-ONCOLOGY COLLABORATION PROFILED IN NATURE BIOPHARMA DEALMAKERS Read AnaptysBio’s Biopharma Dealmakers profile here: Biopharma-Dealmakers-AnaptysBio-Sep-2014.pdf...
View ArticleMomenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program...
September 8th 2014 MOMENTA PHARMACEUTICALS EXERCISES OPTION TO ACQUIRE NOVEL ANTIBODY PROGRAM FROM ANAPTYSBIO SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease...
View ArticleAnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development...
October 20th 2014 ANAPTYSBIO APPOINTS DR. MARCO LONDEI TO NEWLY CREATED CHIEF DEVELOPMENT OFFICER POSITION Clinical Immunologist to Lead AnaptysBio’s Pipeline Advancement SAN DIEGO, Calif. –...
View ArticleTESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel...
December 2nd 2014 TESARO AND ANAPTYSBIO EXPAND IMMUNO-ONCOLOGY COLLABORATION TO INCLUDE NOVEL BISPECIFIC ANTIBODY CANDIDATE Candidate Will Target Two Undisclosed Immune Checkpoints Anti-TIM-3...
View ArticleAnaptysBio Recruits Dr. Gerrit Los to Lead Translational Biology
April 6th 2015 ANAPTYSBIO RECRUITS DR. GERRIT LOS TO LEAD TRANSLATIONAL BIOLOGY Adds Immuno-Oncology Development Strength to AnaptysBio’s Product Pipeline SAN DIEGO, Calif. – AnaptysBio, Inc., a...
View ArticleAnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program to...
April 16th 2015 ANAPTYSBIO ADVANCES FIRST-IN-CLASS ANTI-IL-36 RECEPTOR ANTIBODY PROGRAM TO TREAT ORPHAN INFLAMMATORY DISEASE Genetic Validation Links Incidence of Generalized Pustular Psoriasis With...
View ArticleAnaptysBio Announces Appointment of Hollings Renton and John Schmid to Board...
June 30th 2015 ANAPTYSBIO ANNOUNCES APPOINTMENT OF HOLLINGS RENTON AND JOHN SCHMID TO BOARD OF DIRECTORS Adds Strategic Planning and Corporate Finance Expertise to Board SAN DIEGO, California —...
View ArticleAnaptysBio Appoints Robert E. Hoffman as Chief Financial Officer
July 13th 2015 ANAPTYSBIO APPOINTS ROBERT E. HOFFMAN AS CHIEF FINANCIAL OFFICER Adds Corporate Finance Depth to Senior Management Team SAN DIEGO, California — AnaptysBio, Inc., a leader in the...
View ArticleAnaptysBio Secures $40 Million Series D Financing
July 15th 2015 ANAPTYSBIO SECURES $40 MILLION SERIES D FINANCING Enables Advancement of First-In-Class Anti-Inflammatory Antibody Programs Through Key Clinical Studies SAN DIEGO, California —...
View ArticleAnaptysBio Files Registration Statement for Proposed Initial Public Offering
September 9th 2015 AnaptysBio Files Registration Statement for Proposed Initial Public Offering SAN DIEGO, California — AnaptysBio, Inc., a biotechnology company developing first-in-class antibody...
View ArticleAnaptysBio Announces Appointment of James A. Schoeneck to Board of Directors
November 19th 2015 AnaptysBio Announces Appointment of James A. Schoeneck to Board of Directors Adds Corporate Development and Commercialization Expertise to Board SAN DIEGO, California — AnaptysBio,...
View ArticleAnaptysBio Announces First-In-Human Dosing of Anti-IL-33 Antibody
March 10th 2016 AnaptysBio Announces First-In-Human Dosing of Anti-IL-33 Antibody SAN DIEGO, California — AnaptysBio, Inc., a biotechnology company developing first-in-class antibody product...
View ArticleAnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer
April 18th 2016 AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer SAN DIEGO, California — AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody...
View ArticleAnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1...
July 6th 2016 AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial SAN DIEGO, California — AnaptysBio, Inc., a clinical-stage biotechnology company developing...
View ArticleAnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio
September 26th 2016 AnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio – SHM-XEL platform generates first-in-class approach to selectively inhibit immune cells involved in inflammatory...
View ArticleAnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
October 3rd 2016 AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results – Favorable Safety and Pharmacodynamic Parameters Demonstrated in Healthy Volunteers – US IND and UK CTA Filings...
View ArticleAnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020
December 13th 2016 AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020 Regulatory Clearances Support Initiation of Phase 2a Trials for the Treatment of Adult Peanut Allergy and Atopic...
View ArticleAnaptysBio Announces the Appointment of Dominic Piscitelli as Chief Financial...
January 11th 2017 AnaptysBio Announces the Appointment of Dominic Piscitelli as Chief Financial Officer SAN DIEGO, California — AnaptysBio, Inc., a clinical-stage biotechnology company developing...
View Article